Heejoon Jang

Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study

Jung-Hwan Yoon, Y. Kim, Jeong‐Hoon Lee, 2021, Journal of hepatocellular carcinoma.

Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response

D. Sinn, W. Kang, M. Choi, 2021, Journal of Viral Hepatitis.

Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis

Jung-Hwan Yoon, Y. Kim, Jeong‐Hoon Lee, 2022, Hepatology.

Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation

Jung-Hwan Yoon, Y. Kim, Jeong‐Hoon Lee, 2022, Digestive Diseases and Sciences.

Successful Remission of Recurrent Anaphylaxis after Omalizumab Administration in a Patient with Systemic Mastocytosis

S. Yoo, Heejoon Jang, H. Kang, 2018 .

Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients with Chronic Hepatitis B.

M. Buti, F. Zoulim, R. Idilman, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Young Youn Cho, Y. Kim, Jeong‐Hoon Lee, 2021, Journal of hepatocellular carcinoma.

Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis.

Y. Kim, Jeong‐Hoon Lee, S. Yu, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment

Tae-You Kim, Y. Kim, Jeong‐Hoon Lee, 2020, Clinical and molecular hepatology.

Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study

Y. Kim, Jeong‐Hoon Lee, S. Yu, 2023, Journal of Korean medical science.